183 Multi-center, retrospective analysis of patients with drug reaction with eosinophilia and systemic symptoms (DRESS)

D.A Emge,B Liu,C Green,L Banez,M Mauskar,C Ziemer,R Micheletti,F Nutan,K Deniro,A Mostaghimi,J Keller,B Nardone,C Nguyen,L Seminario-Vidal,J Curtis,L Madigan,R Deshazo R Deshazo,A Cardones

doi:10.1016/j.jid.2022.05.190

183 Multi-center, retrospective analysis of patients with drug reaction with eosinophilia and systemic symptoms (DRESS)

D.A Emge, B Liu + Show 16 more

Open Access

https://doi.org/10.1016/j.jid.2022.05.190

Copy DOI

Journal: The Journal of investigative dermatology	Publication Date: Jul 20, 2022
License type: publisher-specific-oa

Affiliation: Duke University, Agency for Healthcare Research and Quality, The University of Texas Southwestern Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, Virginia Commonwealth University Medical Center, University of Washington, Brigham and Women's Hospital, Oregon Health & Science University, Northwestern University, Eli Lilly (United States), University of Utah

#Drug Reaction With Eosinophilia And Systemic Symptoms #Definite Drug Reaction With Eosinophilia And Systemic Symptoms + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

We conducted a multi-center, 10-year retrospective study of 11 institutions across the USA to identify and describe characteristics, management, and outcomes among DRESS patients. There were a total of 391 pediatric and adult inpatients with final diagnosis of DRESS on discharge. The majority (332/391, 84.9%) had a RegiSCAR score qualifying as either possible, probable, or definite DRESS. Only 110/391 (28.1%) would be classified as typical or atypical DRESS by J-SCAR criteria. Morbilliform eruption or BSA >30% (each in 325/391, 83.1%) were the most common skin findings.

Full Text